Uterine Hyperplasia - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Uterine Hyperplasia – Comprehensive Medical Guide

Uterine Hyperplasia – A Comprehensive Medical Guide

Overview

Uterine hyperplasia, more accurately termed **endometrial hyperplasia**, is a condition in which the lining of the uterus (the endometrium) becomes abnormally thick due to an excess of glandular cells. It most often results from prolonged exposure of the uterus to estrogen without sufficient progesterone opposition.

While endometrial hyperplasia can affect any menstruating woman, it is most common in women approaching or after menopause. According to the CDC and Mayo Clinic, approximately 3–5 % of post‑menopausal women have some form of hyperplasia when screened with endometrial biopsy, and the prevalence rises to about 10 % in women with abnormal uterine bleeding.

Key points:

  • Typically occurs in women **45‑65 years old**.
  • More common in women with **obesity, polycystic ovary syndrome (PCOS),** or those taking unopposed estrogen therapy.
  • Can be **simple** (non‑atypical) or **complex** (with atypia). Atypical hyperplasia carries a higher risk of progression to endometrial cancer.

Symptoms

Many women are asymptomatic, and hyperplasia is discovered incidentally during evaluation for other gynecologic issues. When symptoms do occur, they are usually related to abnormal uterine bleeding.

Typical symptom list

  • Irregular menstrual bleeding – spotting or bleeding between periods.
  • Heavy menstrual flow (menorrhagia) – soaking more than one pad or tampon per hour.
  • Prolonged periods – bleeding lasting longer than 7 days.
  • Post‑menopausal bleeding – any vaginal bleed after 12 months of amenorrhea.
  • Pelvic pain or cramping – usually mild, but can be more noticeable during heavy bleeding.
  • Spotting after intercourse – especially in post‑menopausal women.
  • Passing clots – larger blood clots (>1 cm) during menstruation.

Because these symptoms overlap with many other conditions (fibroids, polyps, cancer), an accurate diagnosis requires formal evaluation.

Causes and Risk Factors

Endometrial hyperplasia is fundamentally an **hormonal imbalance**, mainly excessive estrogen relative to progesterone.*

Primary causes

  • **Obesity** – adipose tissue converts androgens to estrogen (aromatization), raising systemic estrogen levels.
  • **Polycystic Ovary Syndrome (PCOS)** – chronic anovulation leads to prolonged estrogen exposure without progesterone.
  • **Unopposed estrogen therapy** – estrogen‑only hormone replacement therapy (HRT) or tamoxifen use.
  • **Anovulatory cycles** – common in perimenopause.
  • **Diabetes mellitus** – insulin resistance can increase estrogen production.

Additional risk factors

  • Age > 45 years.
  • Family history of endometrial or colorectal cancer.
  • Early menarche (before age 12) or late menopause (after age 55).
  • Nulliparity (never given birth).
  • Use of certain medications (e.g., clomiphene citrate for fertility).
  • Lifestyle factors: sedentary behavior, high‑fat diet, smoking (though smoking has a complex relationship with estrogen metabolism).

Source: National Institutes of Health (NIH) – NIH Fact Sheet

Diagnosis

Because symptoms mimic many other gynecologic disorders, a systematic approach is essential.

Step‑by‑step diagnostic pathway

  1. Medical History & Physical Exam – detailed menstrual, reproductive, and medication history; pelvic exam.
  2. Transvaginal Ultrasound (TVUS) – first‑line imaging. An endometrial thickness >5 mm in post‑menopausal women or >12 mm in pre‑menopausal women warrants further investigation.
  3. Endometrial Biopsy – office‑based pipelle or curettage to obtain tissue for histopathology. This is the gold standard for confirming hyperplasia and identifying atypia.
  4. Hysteroscopy – direct visualization of the uterine cavity; allows targeted biopsies of suspicious areas.
  5. Laboratory Tests – CBC to assess anemia, thyroid function tests, fasting glucose/HbA1c (to screen for diabetes), and hormonal panels (estradiol, progesterone).

When atypia is found, additional staging (CT or MRI) may be performed to rule out invasive carcinoma before deciding on definitive therapy.

Treatment Options

Treatment depends on the type of hyperplasia (simple vs. complex, with or without atypia), patient’s age, desire for future fertility, and presence of comorbidities.

1. Medications

  • Progestin Therapy – first‑line for most non‑atypical hyperplasia.
    • Oral options: medroxyprogesterone acetate 10‑20 mg daily or megestrol acetate 40‑160 mg daily.
    • Levonorgestrel‑releasing intrauterine system (LNG‑IUS, Mirena®) – releases 20 µg/day; effective for up to 5 years.
  • High‑Dose Progestins for Atypical Hyperplasia – may be used when fertility preservation is desired (e.g., medroxyprogesterone 200 mg/day for 14 days each month).
  • Aromatase Inhibitors – off‑label use (letrozole) in obese patients where estrogen production is peripheral.
  • Metformin – beneficial for women with PCOS or insulin resistance; improves progesterone responsiveness.

2. Surgical Options

  • Dilation & Curettage (D&C) – diagnostic and therapeutic; often performed with hysteroscopic guidance.
  • Hysterectomy – definitive treatment for complex atypical hyperplasia or when childbearing is complete. Can be total or subtotal; may be performed via abdominal, vaginal, or minimally invasive (laparoscopic/robotic) approaches.
  • Endometrial Ablation – suitable for women with heavy bleeding who do NOT desire future fertility; destroys the functional layer of the endometrium.

3. Lifestyle Modifications (Adjunctive)

  • Weight loss – 10 % reduction in body weight can decrease peripheral estrogen production.
  • Regular aerobic exercise – at least 150 min/week.
  • Balanced diet – high in fiber, low in saturated fat; consider a Mediterranean pattern.
  • Control of diabetes or insulin resistance.

Choosing a Treatment

Guidelines from the Cleveland Clinic and the National Comprehensive Cancer Network (NCCN) suggest:

  • Simple, non‑atypical hyperplasia – progestin therapy ± LNG‑IUS, with repeat biopsy in 3–6 months.
  • Complex or atypical hyperplasia – consider high‑dose progestins (if fertility desired) or hysterectomy (if not).

Living with Uterine Hyperplasia

Managing day‑to‑day life focuses on symptom relief, monitoring, and overall health.

Practical tips

  • Track bleeding – use a period‑tracking app or journal to note flow, duration, and any spotting.
  • Iron supplementation – if you have heavy periods leading to anemia; check ferritin levels regularly.
  • Maintain follow‑up appointments – repeat endometrial sampling as advised (usually every 3–12 months).
  • Stay active – moderate exercise can improve hormone balance.
  • Stress management – chronic stress can disrupt menstrual cycles; consider yoga, meditation, or counseling.
  • Medication adherence – set daily reminders for oral progestins; schedule IUD checks at 6‑month intervals.

Prevention

Because most cases are linked to hormonal imbalance, many preventive measures target estrogen control.

  • Maintain a healthy weight – Aim for a BMI < 25 kg/m².
  • Use combined estrogen‑progestin HRT if hormone therapy is needed after menopause; avoid estrogen‑only regimens.
  • Screen high‑risk women – annual pelvic exam and ultrasound for those with PCOS, obesity, or a history of atypical hyperplasia.
  • Adopt a diet rich in phytoestrogens (soy, flaxseed) cautiously—some data suggest they may modulate estrogen receptors.
  • Control diabetes and insulin resistance – metformin, diet, and exercise.

Complications

If left untreated, endometrial hyperplasia can progress to more serious conditions.

  • Endometrial carcinoma – especially when atypia is present; risk of progression ranges from 1‑3 % for simple hyperplasia to 28‑30 % for atypical forms (NIH data).
  • Severe anemia – due to chronic heavy bleeding, leading to fatigue, dyspnea, and decreased quality of life.
  • Infertility – altered endometrial environment can impair implantation.
  • Recurrent hyperplasia – up to 20 % of women may develop a second episode after initial treatment.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, heavy vaginal bleeding that soaks through a pad or tampon in under 5 minutes.
  • Severe pelvic or lower‑abdominal pain accompanied by fainting, dizziness, or rapid heartbeat.
  • Signs of significant anemia: shortness of breath at rest, pale skin, or chest pain.
  • Fever > 38 °C (100.4 °F) with pelvic pain – could indicate infection after a procedure.

These situations require immediate medical attention to prevent shock, severe blood loss, or infection.

References

1. Mayo Clinic. Endometrial Hyperplasia. https://www.mayoclinic.org.
2. Centers for Disease Control and Prevention (CDC). Uterine Cancer Prevention. https://www.cdc.gov.
3. National Institutes of Health (NIH). Endometrial Hyperplasia Fact Sheet. https://www.nhlbi.nih.gov.
4. Cleveland Clinic. Endometrial Hyperplasia Treatment Options. https://my.clevelandclinic.org.
5. World Health Organization (WHO). Cancer Fact Sheets – Endometrial Cancer. https://www.who.int.
6. NCCN Clinical Practice Guidelines in Oncology: Gynecologic Cancers. https://www.nccn.org.

```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References